Calypte Only Company with Full Menu of Tests.
Seite 68 von 144 Neuester Beitrag: 03.03.11 19:06 | ||||
| Eröffnet am: | 08.04.05 22:44 | von: Brokersince1. | Anzahl Beiträge: | 4.592 |
| Neuester Beitrag: | 03.03.11 19:06 | von: schubby1 | Leser gesamt: | 220.872 |
| Forum: | Hot-Stocks | Leser heute: | 292 | |
| Bewertet mit: |  | |||
| Seite: < 1 | ... | 65 | 66 | 67 | | 69 | 70 | 71 | ... 144 > | ||||
Die sind schlecht, gebe ich zu, aber im Rahmen der Erwartungen.
Sollte Unmittelbar die Zulassung kommen was möglich wäre und eine Abmachung gefolgt ; )
Leute, so ist das Spiel an der Boerse
Sales of the Legacy Business products discussed above occurred under the terms
of a manufacturing services agreement with Maxim which became effective May 1,
2005. Assuming we either complete a sale of the Legacy Business to Maxim or
another party or terminate Legacy Business operations at Rockville in the
absence of a sale, we expect that by year-end 2005, we will no longer record
sales of these products for our account and will reclassify their results of
operations as discontinued operations.
wir ja zu hören bekommen..
Gross margin improved from a loss of $1,734,000 (-480% of sales) in 2004 to a
loss of $292,000 (-45% of sales) in 2005 primarily as a result of transition
costs attributable to our Legacy Business in both years. Under the terms of the
manufacturing services agreement with Maxim, our gross margin on the Legacy
Business has been significantly reduced compared with the higher labor and
overhead costs incurred during the third quarter of 2004, when we were
manufacturing the Western Blot products at Rockville, Maryland and transitioning
the EIA manufacturing processes there, following our second quarter closure of
our Alameda, California EIA screening test manufacturing facility. Additionally,
the increase in sales of our BED incidence tests has improved our gross margin.
Research and development costs decreased by $104,000 or 20%, from $509,000 in
2004 to $405,000 in 2005. The decrease reflects the elimination of our former
R&D staff and related operations at Rockville in response to the implementation
of our business restructuring. We continued to incur travel and other costs
related to the transfer of our manufacturing technology to Thailand and China
and for various international clinical trials of our rapid tests during the
third quarter of 2005. We also incurred costs related to the transfer of
technology for our BED incidence test to a contract manufacturer in the
Portland, Oregon area in the third quarter of 2005.
Selling, general and administrative costs decreased by $392,000 or 26%, from
$1,487,000 in 2004 to $1,095,000 in 2005. The primary components of the decrease
include the following:
o a decrease of approximately $150,000 in selling expenses, primarily due
to the reduction in outside consultant expenses;
o a reduction of approximately $175,000 in compensation and travel and
entertainment expenses primarily related to the elimination of the
position of Executive Chairman in the fourth quarter of 2004 as well as
the elimination of the former Rockville and Pleasanton administrative
staff.
Our loss from operations for the third quarter of 2005, at $1,792,000, reflects
a 51% decrease compared with the $3,730,000 loss reported for the third quarter
of 2004.
We recorded net interest expense of $1,067,000 for the third quarter of 2005
compared with $79,000 of interest income in the third quarter of 2004
principally due to the accounting for the derivative and anti-dilution
obligations of our recent financings which are required to be adjusted to their
fair value at each balance sheet date with the change in value being recognized
in interest expense. The table below summarizes the components of interest
expense (in thousands):
Aber ich wünsch euch trotzdem alles Gute - ist ja nicht mein Geld :-)
Never argue with an idiot -- they drag you down to their level, then beat you with experience.
We believe that our current cash and borrowing capacity, in conjunction with our
implementation of the Plan, will be sufficient to meet our operating
requirements and permit us to take advantage of strategic opportunities as they
occur into 2006. In 2006, we expect that we will need to arrange additional
equity-based financing to fund our operations and make the investments necessary
to continue to execute our business plan. The Company must achieve profitability
and sustainable cash flows for its business model to succeed. If sufficient
funds are not available from our operations to fund our operations and to enable
us to execute our business plan after 2005 or to repay amounts that may be due
under the financing arrangements, we may need to arrange additional financing,
attempt to extend or otherwise modify the terms of the financing arrangements or
make other arrangements. There can be no assurance that we will be able to do
this. Further, there can be no assurance that we will be able to achieve
expanded acceptance of or realize significant revenues from our potential new
products, including our rapid tests. In addition, there is no assurance that we
will achieve or sustain profitability or positive cash flows in the future. Our
future liquidity and capital requirements will depend on numerous factors,
including successful commercialization of our new rapid tests, protection of
intellectual property rights, costs of developing our new products, including
the necessary intellectual property rights, ability to transfer technology, set
up and scale up manufacturing, obtain regulatory approvals for our new products,
market acceptance of our products, existence of competing products in our
current and anticipated markets, actions by the FDA and other international
regulatory bodies, and our ability to raise additional capital in a timely
manner. Management expects that we will be able to raise additional capital;
however, we may not be able to obtain additional financing on acceptable terms,
or at all.
Signifikante Umsätze da sein, werde ich aufgeben. Da, allein China sehr große Nachfrage gezeigt hat und für eine beschleunigte Zulassung grünes Licht erteilt hat, kann ich und werde ich davon ausgehen das sobald die Zulassung erteilt worden ist ein Großauftrag folgen wird.. Werweiß vielleicht doch wie angekündigt worden ist ein 5 Jahresvertrag ; )
There can be no assurance that our cash on hand at September 30, 2005 of
$658,000 and the availability of $5,500,000 under the terms of the existing
Credit Facility Agreement will be adequate to sustain our operations at expected
levels beyond 2005. Furthermore, any notes we may issue under the Credit
Facility Agreement during the remainder of 2005 must be repaid on May 31, 2006.
We believe we will need to arrange additional equity-based financing to fund our
operations and make the investments necessary to continue to execute our
business plan in 2006. In addition, there can be no assurance that we will
achieve or sustain profitability or positive cash flows in the future.
peinlich, peinlich...das sieht mehr nach exitus aus...
zweckoptimismus ist an diesem platze schon mehr als weltfremd. aber das kennen wir ja schon von dir.
eure zahlen werden immer schlechter und ihr labert euch euren dreck immer noch schön, aber naja. wie kade schon sagte:
auf 2 letzte starke novemberwochen für caly:
STROOOOOOOOOOOOONNNGGGGGG and LLLLLOOOOOOOOOOOOOOOOONNGGGGGGG!!!!!!!!!!!
muhahahaha
viel spaß bei euren zukünftigen 0,10$...
und dahinter direkt die Verkündung eines Großauftrages und schon kann sich alles ändern.
Für mich pers. sind die Zahlen an dritter Stelle, was an dieser Stelle Lebensnotwendig ist, sind die Nachrichten aus China und die werden noch in diesem Jahr kommen Joelü ...
Wie gern würde ich dir ins Gesicht sagen: Lerne von einem gebrochenem alten man , die Kunst des überlebens...
Gruß
C.O
broker, komme was da wolle, für euch bedeutet das gegenwärtig: durch die dilution werden eure aktien immer wertloser...
die umsätze sind deutlich höher als im vergleichsquartal des vorjahres.
der verlust wurde reduziert.
richtig, das ist sicherlich das positive.
was aber schwer wiegt: die cashposition ist bald aus und ganz dünn, weil eben immer noch verluste gefahren werden!!!
das wird nur über die massive aus´gabe neuer aktien zu finanzieren sein. nur: je tiefer der kurs ist, um so mehr aktien muß caly ausgeben, um sich zu finanzieren. die wiederum werden sofort auf den markt geworfen, weil KEINER mehr haltefristen akzeptiert! das wiederum verwässert den kurs noch mehr: jetzt müssen aber wieder mehr aktien ausgegeben werden, um den gleichen finanziellen betrag zu erhalten, wie vor der verwäserung.
verstehst du, was ich meine?
und: immer noch keine rapid-verkäufe! aber wen wundert es!! es wurde euch versprochen, wie schon für 2004 und wieder nicht eingehalten! ich habe es euch schon vor monaten gesagt: IN 2005 KEINE RAPID-TEST-VERKÄUFE.
dafür wolltet ihr mich steinigen und ich war ja der basher...
aber es ist kein bashen, sondern pure realität.
ich bin auch kein hellseher. es steht doch so in den filings!!!
nur: ihr müsst sowas auch mal akzeptieren, auch wenn die wahrheit nicht eurem traum entspricht!!!!
in 2006 werden allerdings noch andere in china verkaufen, garantiert...caly verspielt alles...seine riesen vorsprung, den sie mal hatten.
was mient ihr, warum der vorstand letztens gewechselt hat? bestimmt nicht, weil der alte sooooooooo erfolgreich war...
ihr werdet sicherlich nicht sofort die 0,10$ sehen, aber es spricht nichts mehr für 0,19$ oder mehr...
ich bleibe dabei: dieses jahr noch seht ihr die 0,10$...
Also weder Caly noch die anderen Anbieter werden das alleine schaffen.
Rapid Tests We expect that our future revenues will be derived primarily from the sale of our HIV-1/2 rapid tests. Our focus for 2005 and 2006 remains on commercializing those tests, initially in a dipstick-format and produced in Thailand, from which we believe we can source certain African and southeast Asian markets. We plan to supply the Chinese market with product manufactured locally, in conjunction with our Chinese joint venture operation. In all markets, commencement of rapid test sales is contingent upon the successful completion of clinical trials followed by the required regulatory approvals coupled with successful technology transfer and scale-up of manufacturing operations. Rapid test revenues in 2005 will not be significant. We have received small stocking orders from distributors in our initial target markets of Africa.
In China, we have completed the clinical trials on our HIV rapid tests that were conducted by the National Center for AIDS/STD Control and Prevention of the Chinese CDC. The trials involved approximately 1,500 subjects. Based on the results of the trials, we believe that the performance of each of our three rapid tests was sufficient to make them approvable; however, the performance of the urine test was not as robust as that of the blood or oral fluid tests. Since our oral fluid test has consistently performed well in clinical trials and the Chinese SFDA has expressed an interest in alternative fluid testing, we have decided to initially submit only our oral fluid HIV test for approval by the Chinese SFDA. We are in the process of preparing that application for submission to expedite the development of a revenue stream in China. Beijing Calypte, our joint venture with Marr Technologies Asia Limited ("Marr Asia"), an affiliate of Marr Technologies BV, our largest stockholder, will manage the Chinese oral fluid test product launch. There are several large markets in China, including a publicly announced commitment by the Chinese government to offer voluntary HIV testing to its entire 1.36 billion person population. With trained non-professionals and a safe, non-invasive oral fluid test, we expect strong demand for our initial test.
We believe that urine is also a valuable alternative to blood testing and has a definite place in HIV testing. Further, we have received verbal guidance from the SFDA that the urine rapid test is desirable and approvable. We plan to
submit an application for marketing approval of our urine rapid test once we have strategically determined the appropriate path for getting it on the Chinese market.
Angehängte Grafik:
91.gif
91.gif
fakten sind ja eh egal...bei euch zählt ja eh nur die zukunft und das jedes jahr aufs neue.....muhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhaaaahahahahahahahaha
Rec. Time Action Price Volume
9:41:50 AM Trade 0.18 10000
9:41:50 AM Bid 0.18 242500
9:39:12 AM Bid 0.18 252500
9:39:12 AM Ask 0.19 82400
9:39:10 AM Trade 0.18 47500
9:37:00 AM Trade 0.18 600
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
9:36:52 AM Trade 0.19 100
Rec. Time Action Price Volume
9:49:50 AM Bid 0.18 80000
9:49:46 AM Bid 0.18 26000
9:49:42 AM Trade 0.18 600
9:49:40 AM Trade 0.18 3100
9:49:40 AM Trade 0.18 4300
9:49:38 AM Trade 0.18 11100
9:49:34 AM Bid 0.18 6000
9:49:34 AM Bid 0.18 5700
9:49:34 AM Bid 0.18 5400
9:49:34 AM Bid 0.18 4700
9:49:34 AM Bid 0.18 600
9:49:34 AM Ask 0.19 107400
9:49:32 AM Ask 0.18 100
9:49:30 AM Trade 0.18 34300
9:49:28 AM Trade 0.18 3000
9:49:28 AM Ask 0.18 34300
9:49:26 AM Trade 0.18 500
9:49:26 AM Trade 0.18 10300
9:49:24 AM Trade 0.18 9200
9:49:22 AM Trade 0.18 10000
9:49:22 AM Ask 0.18 37300
9:49:12 AM Trade 0.18 8800
9:49:12 AM Trade 0.18 300
9:49:12 AM Trade 0.18 8300
9:49:08 AM Trade 0.18 900
9:49:04 AM Trade 0.18 10000
9:49:04 AM Trade 0.18 11100
9:49:04 AM Trade 0.18 100
nicht Joelu
Mr. Roger Gale, Calypte's Chairman and CEO said, "I am pleased with the progress that we have made this quarter and believe that achievements made during this period should have a positive impact on our future. Following approval of our rapid tests in Zimbabwe and Malaysia and execution of distribution agreements covering a number of African countries, we began making limited international shipments of our rapid HIV-1/2 tests and generated a small amount of revenue from those sales during the third quarter. This marks an important milestone and we hope to be able to follow through with additional country approvals and international shipments. Sales of our BED Incidence test, which began in the fourth quarter of 2004, also continue to expand, increasing by 86% over the level reported for the second quarter of 2005 to reach $165,000, representing approximately 25% of our third quarter revenues."
Mr. Gale added, "We are also gratified with the results released in the final clinical trial report issued by The Chinese Centers for Disease Control. This report confirmed the performance of Calypte's rapid test platform, Aware HIV-1/2 BSP, Aware HIV-1/2 OMT, and Aware HIV-1/2 U rapid tests in addition to its HIV-1 Serum Western blot and HIV-1 Urine Western blot tests. The clinical trial was completed earlier this year and the results will serve as the basis for the regulatory filings that the Company intends to submit to the Chinese SFDA before the end of the year."
The Company plans to host an investor update conference call later this month. The date and time of that call will be announced in a subsequent press release.
The Company plans to host an investor update conference call later this month. The date and time of that call will be announced in a subsequent press release.
Da wird ganz bestimmt was aus China kommen ; )
Gruß
C.O
sehr schön auch die tageshistorie, in der jeder einzelne trade hinterlegt ist mit bid/ask-spannen